10/54**9**871

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference		O.V.	See Form PCT/IPEA/416	
0000054379	FOR FURTHER ACTI			
International application No.	International filing date (d	lay/month/year)	Priority date (day/month/year)	
PCT/EP2004/002582	12.03.2004		19.03.2003	
International Patent Classification (IPC)	or national classification and IPC		,	
Applicant BASF AKTIENGESELLS	SCHAFT			
This report is the international under Article 35 and transmitted.	l preliminary examination report, ed to the applicant according to A	established by this l rticle 36.	International Preliminary Examining Authority	
2. This REPORT consists of a tot	al of 5	sheets, including	g this cover sheet.	
3. This report is also accompanie	d by ANNEXES, comprising:			
a. (sent to the applica	ant and to the International Burea	u) a total of	sheets, as follows:	
sheets of the sheets contai Instructions).	a. (sent to the applicant and to the International Bureau) a total of sheets, as follows: sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).			
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.				
b. (sent to the Intern	ational Bureau only) a total of (in	dicate type and numbe	er of electronic carrier(s))	
	, containing a sequence listing and/or tables			
related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
4. This report contains indication	ns relating to the following items:			
Box No. I Bas	is of the report			
Box No. II Pric	ority			
	·	gard to novelty, inver	ntive step and industrial applicability	
<u> </u>	k of unity of invention			
Roy No. V. Rez		(2) with regard to nov s such statement	velty, inventive step or industrial applicability;	
Box No. VI Cer	tain documents cited			
Box No. VII Cer	tain defects in the international a	pplication		
	rtain observations on the internati			
Date of submission of the demand		Date of completion of	this report	
2		-		
Name and mailing address of the IPE	VEP A	Authorized officer		
Faccimila No.		Telephone No.		
Facsimile No.				

Translation

International application No.
PCT/EP2004/002582

Box	No. I	Basis of the report		
1.	With	regard to the language, this report is based on the internation ated under this item.	al application in the language in which it was filed, unless otherwise	
	This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of:			
		international search (Rule 12.3 and 23.1(b))		
		publication of the international application (Rule 12.4)		
		international preliminary examination (Rule 55.2 and/o		
2.	recei	regard to the elements of the international application, this in iving Office in response to an invitation under Article 14 are report):	eport is based on (replacement sheets which have been furnished to the referred to in this report as "originally filed" and are not annexed to	
	Ц	the international application as originally filed/furnished		
	\boxtimes	the description:		
		pages 1-44	as originally filed/furnished	
		pages*	received by this Authority on	
		pages*	received by this Authority on	
	\boxtimes	the claims:		
		nos. 1-30	as originally filed/furnished	
		nos.*	as amended (together with any statement) under Article 19	
		nos.*	received by this Authority on	
		nos.*	received by this Authority on	
	\boxtimes	the drawings:		
		sheets _1/2-2/2	as originally filed/furnished	
		sheets*	-	
			received by this Authority on	
ŀ	\Box	a sequence listing and/or any related table(s) - see Supplem		
3.	$\overline{\Box}$	The amendments have resulted in the cancellation of:	and Don Relating to bequeine Daining.	
].		the description, pages		
		the claims, nos.		
		[]		
4.			ments annexed to this report and listed below had not been made, since	
7.		they have been considered to go beyond the disclosure as fil	ed, as indicated in the Supplemental Box (Rule 70.2(c)).	
		the claims, nos.		
ٿ	If ite	em 4 applies, some or all of those sheets may be marked "sup	erseded."	

International application No.
PCT/EP2004/002582

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1.	Statement			
	Novelty (N)	Claims	1-30	YES
		Claims		NO
	Inventive step (IS)	Claims		YES
		Claims	1-30	NO
	Industrial applicability (I	A) Claims	1-30	YES
		Claims		NO

- 2. Citations and explanations (Rule 70.7)
 - 1. Reference to the following documents:

D1: EP-A-O 486 290 (AMOCO CORP)

20 May 1992 (1992-05-20)

D2: DE 197 44 212 A (SCHERING AG)

15 April 1999 (1999-04-15).

- The present application fails to satisfy the requirements of PCT Article 33(2) because the subject matter of claims 1-30 lacks novelty (PCT Article 33(2)).
- 3.1 Document D1 discloses (the references in brackets are to said document) a method for the production of a variety of sterols which can be regarded as intermediate and/or resultant products of ergosta-5,7-dienol, said method involving the cultivation of organisms which have a reduced Δ22-desaturase (erg5) activity and an increased HMG-CoA-reductase activity relative to the wild type (see claim 13).
- 3.2 Document **D2** discloses a method for the production of a variety of sterols which can be regarded as

/...

PCT/EP2004/002582

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

intermediate and/or resultant products of ergosta-5,7-dienol, said method involving the cultivation of organisms which have an increased HMG-CoA-reductase activity and increased squalene poxidase (erg1) activity relative to the wild type (see claim 2.a-iv)).

- 4.1 The present application fails to satisfy the requirements of PCT Article 33(1) because the subject matter of claims 1-30 does not involve an inventive step (PCT Article 33(3)).
- 4.2 Document D1 is considered to be the prior art closest to the subject matter of claim 1 and the subject matter of claim 1 therefore differs from D1 in that the method is implemented using organisms which, by comparison with the present claims, additionally display an increased activity of a further enzyme, which enzyme can be selected from the group comprising lanosterol-C14-demethylase (erg11), squalene poxidase (erg1) and squalene synthetase (erg9).
- 4.3 The problem addressed by the present invention can consequently be regarded as that of providing an alternative method for producing ergosta-5-7-dienol (and/or biosynthetic intermediate and/or resultant products thereof).

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- 4.4 The solution proposed in claims 1-10 and 15-18 of the present application cannot be considered inventive (PCT Article 33(3)) for the following reasons:
 - as stated in point 3.2 above, D2 discloses (see claim 2.a-iv)) a method for the production of ergosta-5-7-dienol and/or biosynthetic intermediate and/or resultant products thereof by means of an increased t-HMG and erg1 activity. A person skilled in the art could therefore arrive at the solution to the present problem by combining the disclosures of D1 and D2, without unreasonable experimental input.
- 4.5 Moreover, the problem cannot be considered to have been solved for the entire scope of protection claimed in claim 1: (i) it has not been shown that the problem has been solved for all intermediate and/or resultant products of ergosta-5,7-dienol. Tables 2 and 3 (data for S. cerevisiae GRFtHIura3ERG1erg5) show the decrease in the content of squalene (which can be considered to be an intermediate product of ergosta-5-7-dienol) by comparison with table 1 (data for S. cerevisiae GRFtHIura3) and table 3 (data for S. cerevisiae GRFtHIura3erg5); (ii) nor has it been shown that the aforementioned problem has been solved by an increase in lanosterol-C14-demethylase (erg11) or squalene synthetase (erg9) activity (in addition

/...

International application No.
PCT/EP2004/002582

Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
	to a reduction in erg5 activity and an increase in
	HMG reductase activity).
4.6	In consequence, claims 1-30 do not involve an
	inventive step (PCT Article 33(3)).

International application No.
PCT/EP2004/002582

Box No. V	VI Certain documents cited			
1. Cert	ain published documents (Rule 70.10)	Publication date	Filing date	Priority date (valid claim)
	Application No. Patent No.	(day/month/year)	(day/month/year)	(day/month/year)
2. No	n-written disclosures (Rule 70.9)			
	Kind of non-written disclosure	Date of non-written d (day/month/yea	isclosure referri	ate of written disclosure ng to non-written disclosure (day/month/year)
ı				

International application No.
PCT/EP2004/002582

Supp	lemental	Box
------	----------	-----

In case the space in any of the preceding boxes is not sufficient. Continuation of:

Box VI

Document D4 (WO03/064650), cited in the search report, might be prejudicial to novelty in a later regional phase.